Please login to the form below

Not currently logged in
Email:
Password:

Merck Serono and Takeda reconsider matuzumab development

Merck Serono has announced it is considering whether to further develop its humanised monoclonal antibody drug matuzumab for metastatic colorectal cancer patients.

Merck Serono has announced it is considering whether to further develop its humanised monoclonal antibody drug matuzumab for metastatic colorectal cancer patients.

According to the company, a phase II trial investigating matuzumab in combination with irinotecan in patients with metastatic colorectal cancer (mCRC) who had already failed on multiple prior treatments, including irinotecan, has not met its predefined endpoint of activity.

Swtizerland-based Merck Serono is co-developing matuzumab with Japanese company Taked. According to a statement by Merck Serono, both companies share the view that the study results do not meet expectations.

The companies will continue to study the drug in other tumours including non-small cell lung cancer (NSCLC).

29th August 2007

Share

Subscribe to our email news alerts

Featured jobs

PMHub

Add my company
nzyme

The nzyme group focuses on the three fundamentals that enable full patient access - Education, Access & Activation. Our specialist...

Latest intelligence

Mainimage2
The role of digital health technology tools in supporting medical adherence
How DHT-based digital interventions can help to support patients and improve adherence...
How To Tell A Better Silent Story
They say a picture's worth 1,000 words, which is incredibly helpful when telling a silent story....
Main image1
Global leaders in digital channels
Exploring why UK field teams are global leaders in digital channels is key to better understanding the changes in omnichannel engagement...